AVANIR PHARMACEUTICALS, INC CL A
AVNR
AVNR was delisted on the 12th of January, 2015.
0 hedge funds and large institutions have $0 invested in AVANIR PHARMACEUTICALS, INC CL A in 2015 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 163 closing their positions.
100% less funds holding
Funds holding: 166 → 0 (-166)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $2.74B → $0 (-$2.74B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 163
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$653M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$398M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$152M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$146M |
| 5 |
WIC
Water Island Capital
New York
|
-$89.9M |
AVNR Hedge Fund Activity: Q1 2015 in Review
0 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in AVANIR PHARMACEUTICALS, INC CL A (AVNR) for Q1 2015, worth a combined $0 — down 100% from $2.74B a quarter earlier.
Sellers outnumbered buyers: 163 funds closed out of AVNR and 0 opened new positions — a net loss of 163 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $653M sold.
- 0 institutional investors held AVANIR PHARMACEUTICALS, INC CL A (AVNR) as of Q1 2015, down from 166 in Q4 2014.
- Funds reported $0 of AVANIR PHARMACEUTICALS, INC CL A stock for Q1 2015, down 100% quarter-over-quarter.
- 0 funds opened new AVANIR PHARMACEUTICALS, INC CL A positions in Q1 2015 and 163 closed out, a net change of -163 holders.
- The largest AVANIR PHARMACEUTICALS, INC CL A seller in Q1 2015 was Baker Bros. Advisors, an estimated $653M sold.
Based on aggregated 13F filings for Q1 2015.